臺灣博碩士論文加值系統

為了建立能夠治療惡性肋膜積水且以聚己內酯薄膜為基礎的長效藥物釋放系統，因此在膜中混參由溶劑置換法所形成的奈米粒子來發展出此系統達到長時間穩定釋放抗癌藥物：順鉑。在體外實驗中發現奈米粒子釋放藥物時間遠比含藥膜的釋放天期長，且在細胞毒殺實驗也發現奈米粒子的毒性較小，推測結果是因為藥物釋放相較於含藥膜較為緩慢。另外，在抑制腫瘤生長的動物實驗也發現同時含藥和奈米粒子的薄膜在十八天後可以看到比含藥水溶液和一般含藥膜有較好的抑制生長情形。本研究也利用大鼠腹腔沾黏實驗觀察用氯化鈉作為致孔劑的多孔膜和有混參奈米粒子的膜的沾黏情況，結果發現兩者的沾黏情形沒有顯著差異，也都比表面較為緻密的膜的沾黏效果好，而根據掃描電子顯微鏡發現其原因可能是奈米粒子會造成膜的表面結構多孔化，促進沾黏反應。與預期相同，混參有奈米粒子的聚己內酯膜可以被用作兩階段藥物釋放系統。實驗結果顯示，此系統可以控制粒子內的藥物接在膜內藥物之後釋放，這說明了此系統有機會取代目前臨床治療惡性肋膜積水的給藥方式成為新的可以同時進行肋膜沾黏和體內釋放藥物的產品。

To develop a sustained drug delivery system based on PCL membrane, promoting pleural adhesion, for the treatment of malignant pleural effusion (MPE), cisplatin (CDDP)-encapsulated PLGA nanoparticles (PLGA/CDDP NPs) were fabricated via solvent displacement method for the purpose of prolonging drug delivery. The PCL membrane incorporating CDDP and PLGA/CDDP NPs (PLGA/CDDP NP-PCL/CDDP membrane) was investigated under the in vitro and in vivo conditions with the comparison of PCL membrane incorporating CDDP (PCL/CDDP membrane) and free CDDP in solution form. As nanoscale drug carriers, the PLGA/CDDP NPs released the drug in a long-term manner for a longer period than PCL/CDDP membrane and were also less cytotoxic than free CDDP and PCL/CDDP membrane which probably due to the slower release of CDDP from NPs. The tumor-suppressing ability was observed that PLGA/CDDP NP-PCL/CDDP membrane could successfully inhibit the tumor growth after 17days because of the sustained release of CDDP in tumor-bearing mice, as shown by changes in tumor volumes, body weights, and survival trends. Histological analysis of tumor sections on Day 21 also showed that PLGA/CDDP NP-PCL/CDDP membrane had an obvious anti-tumor effect than other treatments. In addition, there was no significant difference of abdominal adhesion effect between the PLGA NP-PCL membrane and the porous PCL membrane probably because PCL membrane blended with PLGA NPs also had the porous surface structure facilitating the adhesion response without influencing the living conditions of rats. As expected, PLGA NP-PCL membrane system can also be used as two-step drug delivery system serving as a promising new treatment for MPE.

致謝 1
中文摘要 2
Abstract 3
Content 5
List of Tables 7
List of Figures 8
Chapter 1 Introduction 9
1.1 Malignant Pleural effusion 9
1.2 PCL Membrane 10
1.3 Cisplatin 11
1.4 Drug Delivery System 13
1.5 Objective 14
Chapter 2 Materials and Methods 16
2.1 Biological and Chemical Reagents 16
2.2 Instruments 17
2.3 Animals 18
2.4 Tumor Cells 18
2.5 Cell Culture 19
2.6 Preparation of CDDP-PCL Membrane 20
2.7 Fabrication of PLGA Nanoparticles incorporating CDDP 20
2.8 Preparation of CDDP-PCL Membrane Dispersed with CDDP-PLGA Nanoparticles 20
2.9 Characterization of PCL Membrane and PLGA Nanoparticles 21
2.10 Two-Step Drug Release Profile of PCL Membrane 22
2.11 In Vitro Drug Release Profile 22
2.12 In Vitro Anti-tumor effect 23
2.13 In Vivo Abdominal Adhesion Studies 23
2.14 In Vivo Anti-tumor Efficacy 25
2.15 Immunohistological Examination 25
2.16 Statistical Analysis 26
Chapter 3 Results 27
3.1 Characteristics of PCL Membrane and Nanoparticles 27
3.2 The Release Profile of CDDP-Membrane and Nanoparticles 29
3.3 Two-Step Drug Release Profile of PCL Membrane 31
3.4 In Vitro Cytotoxicity of CDDP-Membrane and Nanoparticles 32
3.5 In Vivo Study of Abdominal Adhesion 33
3.6 In Vivo Study of Anti-tumor Efficacy 34
3.7 Immunohistological Examination 36
Chapter 4 Discussion 37
4.1 Effective Therapy for Malignant Pleural Effusion 37
4.2 Sustained Drug Release System 39
4.3 In Vivo Anti-tumor Efficacy 42
4.4 Effective PCL Membrane Adhesion 44
4.5 Development of Two-Step Drug Release System 45
Chapter 5 Conclusion and Perspective 46
Figures 47
Tables 64
References 66

[1]N.M. Rahman, N.J. Ali, G. Brown, S.J. Chapman, R.J.O. Davies, N.J. Downer, et al., Local anaesthetic thoracoscopy: British Thoracic Society pleural disease guideline 2010, Thorax. 65 (2010) ii54–ii60. doi:10.1136/thx.2010.137018.
[2]N. Maskell, N. Rahman, Individualised management of malignant pleural effusion, Inflammation (Eg. (2015).
[3]G. Antunes, E. Neville, J. Duffy, N. Ali, BTS guidelines for the management of malignant pleural effusions, Thorax. 58 (2003) ii29. doi:10.1136/thorax.58.suppl_2.ii29.
[4]M.E. Roberts, E. Neville, R.G. Berrisford, G. Antunes, N.J. Ali, Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010, Thorax. 65 (2010) ii32–ii40. doi:10.1136/thx.2010.136994.
[5]V.B. Antony, R. Loddenkemper, P. Astoul, C. Boutin, P. Goldstraw, J. Hott, et al., Management of malignant pleural effusions, European Respiratory Journal. 18 (2001) 402–419. doi:10.1136/thx.38.3.175.
[6]A. Kumari, S.K. Yadav, S.C. Yadav, Biodegradable polymeric nanoparticles based drug delivery systems, Colloids and Surfaces B: Biointerfaces. 75 (2010) 1–18. doi:10.1016/j.colsurfb.2009.09.001.
[7]B. Rai, S.H. Teoh, D.W. Hutmacher, T. Cao, K.H. Ho, Novel PCL-based honeycomb scaffolds as drug delivery systems for rhBMP-2, Biomaterials. 26 (2005) 3739–3748. doi:10.1016/j.biomaterials.2004.09.052.
[8]A.G.A. Coombes, S.C. Rizzi, M. Williamson, J.E. Barralet, S. Downes, W.A. Wallace, Precipitation casting of polycaprolactone for applications in tissue engineering and drug delivery, Biomaterials. 25 (2004) 315–325. doi:10.1016/S0142-9612(03)00535-0.
[9]F.A. Barber, J.N. Click, The effect of inflammatory synovial fluid on the breaking strength of new “long lasting” absorbable sutures, Arthroscopy: the Journal of Arthroscopic & Related Surgery. 8 (1992) 437–441. doi:10.1016/0749-8063(92)90004-U.
[10]B.W. Tillman, S.K. Yazdani, S.J. Lee, R.L. Geary, A. Atala, J.J. Yoo, The in vivo stability of electrospun polycaprolactone-collagen scaffolds in vascular reconstruction, Biomaterials. 30 (2009) 583–588. doi:10.1016/j.biomaterials.2008.10.006.
[11]W.Y. Yeong, N. Sudarmadji, H.Y. Yu, C.K. Chua, K.F. Leong, S.S. Venkatraman, et al., Porous polycaprolactone scaffold for cardiac tissue engineering fabricated by selective laser sintering, Acta Biomaterialia. 6 (2010) 2028–2034. doi:10.1016/j.actbio.2009.12.033.
[12]J.M. Williams, A. Adewunmi, R.M. Schek, C.L. Flanagan, P.H. Krebsbach, S.E. Feinberg, et al., Bone tissue engineering using polycaprolactone scaffolds fabricated via selective laser sintering, Biomaterials. 26 (2005) 4817–4827. doi:10.1016/j.biomaterials.2004.11.057.
[13]N. Bolgen, İ. Vargel, P. Korkusuz, Y.Z. Menceloğlu, E. Pişkin, In vivo performance of antibiotic embedded electrospun PCL membranes for prevention of abdominal adhesions, J. Biomed. Mater. Res. 81B (2007) 530–543. doi:10.1002/jbm.b.30694.
[14]H.Y. Lo, H.T. Kuo, Y.Y. Huang, Application of Polycaprolactone as an Anti‐Adhesion Biomaterial Film, Artificial Organs. 34 (2010) 648–653. doi:10.1111/j.1525-1594.2009.00949.x.
[15]S. Jiang, W. Wang, H. Yan, C. Fan, Prevention of Intra-Abdominal Adhesion by Bi-Layer Electrospun Membrane, International Journal of Molecular Sciences 2013, Vol. 14, Pages 11861-11870. 14 (2013) 11861–11870. doi:10.3390/ijms140611861.
[16]E.R. Jamieson, S.J. Lippard, Structure, recognition, and processing of cisplatin-DNA adducts, Chemical Reviews. (1999).
[17]B.E. Markham, R.R. Brubaker, Influence of chromosome integrity on Escherichia coli cell division, J. Bacteriol. 143 (1980) 455–462.
[18]A.L. Pinto, S.J. Lippard, Sequence-dependent termination of in vitro DNA synthesis by cis- and trans-diamminedichloroplatinum (II), Pnas. 82 (1985) 4616–4619.
[19]C.M. Sorenson, A. Eastman, Mechanism of cis-Diamminedichloroplatinum(II)-induced Cytotoxicity: Role of G2 Arrest and DNA Double-Strand Breaks, Cancer Res. 48 (1988) 4484–4488.
[20]T.I.A.L.C.T.C. Group, Cisplatin-Based Adjuvant Chemotherapy in Patients with Completely Resected Non–Small-Cell Lung Cancer, Http://Dx.Doi.org/10.1056/NEJMoa031644. 350 (2009) 351–360. doi:10.1056/NEJMoa031644.
[21]H. Fujii, K. Honoki, T. Tsujiuchi, Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines, International …. (2009).
[22]J. Yoshida, K. Sugita, T. Kobayashi, K. Takakura, N. Shitara, M. Matsutani, et al., Prognosis of intracranial germ cell tumours: Effectiveness of chemotherapy with cisplatin and etoposide (CDDP and VP-16), Acta Neurochir. 120 (1993) 111–117. doi:10.1007/BF02112027.
[23]P. McLaughlin, W.S. Velasquez, J.R. Redman, W.K.A. Yung, F.B. Hagemeister, M.A. Rodriguez, et al., Chemotherapy With Dexamethasone, High-Dose Cytarabine, and Cisplatin for Parenchymal Brain Lymphoma, JNCI J Natl Cancer Inst. 80 (1988) 1408–1412. doi:10.1093/jnci/80.17.1408.
[24]J.M. Kirwan, P. Symonds, J.A. Green, J. Tierney, M. Collingwood, C.J. Williams, A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer, Radiotherapy and Oncology. 68 (2003) 217–226. doi:10.1016/S0167-8140(03)00197-X.
[25]S. Noguchi, T. Mori, Y. Hoshino, K. Maruo, N. Yamada, Y. Kitade, et al., MicroRNA-143 functions as a tumor suppressor in human bladder cancer T24 cells, Cancer Letters. 307 (2011) 211–220. doi:10.1016/j.canlet.2011.04.005.
[26]M. Pistolesi, J. Symanowski, U. Gatzemeier, S. Emri, P-513 Improving pulmonary function in patients with malignant pleural mesothelioma: Results of the phase III trial of pemetrexed+ cisplatin vs. cisplatin, Lung Cancer, 2003.
[27]A. Brade, R. MacRae, S.A. Laurie, A. Bezjak, R. Burkes, Q. Chu, et al., Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non–Small Cell Lung Cancer, Clinical Lung Cancer. 17 (2016) 133–141. doi:10.1016/j.cllc.2015.12.008.
[28]G.V. Scagliotti, P. Parikh, J. von Pawel, B. Biesma, J. Vansteenkiste, C. Manegold, et al., Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer, Jco. 26 (2008) 3543–3551. doi:10.1200/JCO.2007.15.0375.
[29]T. Ciuleanu, T. Brodowicz, C. Zielinski, J.H. Kim, M. Krzakowski, E. Laack, et al., Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study, The Lancet. 374 (2009) 1432–1440. doi:10.1016/S0140-6736(09)61497-5.
[30]L.G. Paz-Ares, F. de Marinis, M. Dediu, M. Thomas, J.-L. Pujol, P. Bidoli, et al., PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer, Jco. 31 (2013) 2895–2902. doi:10.1200/JCO.2012.47.1102.
[31]R.S. Goldstein, B. Noordewier, J.T. Bond, J.B. Hook, G.H. Mayor, cis-Dichlorodiammineplatinum nephrotoxicity: Time course and dose response of renal functional impairment, Toxicology and Applied Pharmacology. 60 (1981) 163–175. doi:10.1016/0041-008X(91)90220-9.
[32]J.-H. Kim, Y.-S. Kim, K. Park, S. Lee, H.Y. Nam, K.H. Min, et al., Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice, Journal of Controlled Release. 127 (2008) 41–49. doi:10.1016/j.jconrel.2007.12.014.
[33]D. Ding, Z. Zhu, Q. Liu, J. Wang, Y. Hu, X. Jiang, et al., Cisplatin-loaded gelatin-poly(acrylic acid) nanoparticles: Synthesis, antitumor efficiency in vivo and penetration in tumors, European Journal of Pharmaceutics and Biopharmaceutics. 79 (2011) 142–149. doi:10.1016/j.ejpb.2011.01.008.
[34]S. Guo, Y. Wang, L. Miao, Z. Xu, C.M. Lin, Y. Zhang, et al., Lipid-Coated Cisplatin Nanoparticles Induce Neighboring Effect and Exhibit Enhanced Anticancer Efficacy, ACS Nano. 7 (2013) 9896–9904. doi:10.1021/nn403606m.
[35]S. Guo, L. Miao, Y. Wang, L. Huang, Unmodified drug used as a material to construct nanoparticles: delivery of cisplatin for enhanced anti-cancer therapy, Journal of Controlled Release. 174 (2014) 137–142. doi:10.1016/j.jconrel.2013.11.019.
[36]M. Markman, Intraperitoneal chemotherapy in the management of malignant disease, Expert Review of Anticancer Therapy. 1 (2014) 142–148. doi:10.1586/14737140.1.1.142.
[37]Y. Nagata, N. Araki, H. Kimura, K. Fujiwara, K. Okajima, T. Aoki, et al., Neoadjuvant Chemotherapy by Transcatheter Arterial Infusion Method for Uterine Cervical Cancer, Journal of Vascular and Interventional Radiology. 11 (2000) 313–319. doi:10.1016/S1051-0443(07)61423-7.
[38]M. Konishi, Y. Tabata, M. Kariya, A. Suzuki, M. Mandai, K. Nanbu, et al., In vivo anti-tumor effect through the controlled release of cisplatin from biodegradable gelatin hydrogel, Journal of Controlled Release. 92 (2003) 301–313. doi:10.1016/S0168-3659(03)00364-X.
[39]S. Voulgaris, M. Partheni, M. Karamouzis, P. Dimopoulos, N. Papadakis, H.P. Kalofonos, Intratumoral Doxorubicin in Patients With Malignant Brain Gliomas, American Journal of Clinical Oncology. 25 (2002) 60.
[40]M. Konishi, Y. Tabata, M. Kariya, H. Hosseinkhani, A. Suzuki, K. Fukuhara, et al., In vivo anti-tumor effect of dual release of cisplatin and adriamycin from biodegradable gelatin hydrogel, Journal of Controlled Release. 103 (2005) 7–19. doi:10.1016/j.jconrel.2004.11.014.
[41]J. MOLPECERES, M. GUZMAN, M.R. ABERTURAS, M. CHACON, L. BERGES, Application of Central Composite Designs to the Preparation of Polycaprolactone Nanoparticles by Solvent Displacement, Journal of Pharmaceutical Sciences. 85 (1996) 206–213.
[42]J.A. Ankrum, O.R. Miranda, K.S. Ng, D. Sarkar, C. Xu, J.M. Karp, Engineering cells with intracellular agent–loaded microparticles to control cell phenotype, Nat Protoc. 9 (2014) 233–245. doi:10.1038/nprot.2014.002.
[43]K. Rodgers Ph D, D. Cohn Ph D, A. Hotovely, E. Pines Ph D, M.P. Diamond M D, G. diZerega M D, Evaluation of Polyethylene Glycol/Polylactic Acid Films in the Prevention of Adhesions in the Rabbit Adhesion Formation and Reformation Sidewall Models1, Fertil Steril. 69 (1998) 403–408. doi:10.1016/S0015-0282(97)00574-8.
[44]B. NR, M. AL, B. JG, L. A, Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods, Cancer Chemother Rep. 54 (1970) 89–94.
[45]X.-E. Huang, G.-L. Wei, J.-G. Huo, X.-N. Wang, Y.-Y. Lu, X.-Y. Wu, et al., Intrapleural or Intraperitoneal Lobaplatin for Treatment of Patients with Malignant Pleural Effusion or Ascites, Asian Pacific Journal of Cancer Prevention. 14 (2013) 2611–2614. doi:10.7314/APJCP.2013.14.4.2611.
[46]H. DL, G. JM, K. KA, M. DM, B. JW, M. PN, Comparison of insufflated talc under thoracoscopic guidance with standard tetracycline and bleomycin pleurodesis for control of malignant pleural effusions, J Thorac Cardiovasc Surg. 105 (1993) 743–7; discussion 747–8.
[47]T. Seto, S. Ushijima, H. Yamamoto, K. Ito, J. Araki, Y. Inoue, et al., Intrapleural hypotonic cisplatin treatment for malignant pleural effusion in 80 patients with non-small-cell lung cancer: a multi-institutional phase II trial, British Journal of Cancer. 95 (2006) 717–721. doi:10.1038/sj.bjc.6603319.
[48]M. Beck-Broichsitter, E. Rytting, T. Lebhardt, X. Wang, T. Kissel, Preparation of nanoparticles by solvent displacement for drug delivery: A shift in the “ouzo region” upon drug loading, European Journal of Pharmaceutical Sciences. 41 (2010) 244–253. doi:10.1016/j.ejps.2010.06.007.
[49]H.S. Ribeiro, B.-S. Chu, S. Ichikawa, M. Nakajima, Preparation of nanodispersions containing β-carotene by solvent displacement method, Food Hydrocolloids. 22 (2008) 12–17. doi:10.1016/j.foodhyd.2007.04.009.
[50]X. Zeng, E. Ruckenstein, Control of Pore Sizes in Macroporous Chitosan and Chitin Membranes, (1997) 1–7.
[51]H. Imai, Y. Takei, K. Shimizu, M. Matsuda, H. Hirashima, Direct preparation of anatase TiO2 nanotubes in porous alumina membranes, J Mater Chem. (1999).
[52]L. YAN, Y. LI, C. XIANG, S. XIANDA, Effect of nano-sized Al2O3-particle addition on PVDF ultrafiltration membrane performance, Journal of Membrane Science. 276 (2006) 162–167. doi:10.1016/j.memsci.2005.09.044.
[53]Y. Wang, W. Yun, C. Jacobsen, Achromatic Fresnel optics for wideband extreme-ultraviolet and X-ray imaging, Nature. 424 (2003) 50–53. doi:10.1038/nature01756.